Denali Therapeutics Inc

Closed

SectorHealthcare

25.99 1.13

Overview

Share price change

24h

Current

Min

25.56

Max

26.14

Key metrics

By Trading Economics

Income

102K

-128M

EPS

-0.69

Employees

507

EBITDA

-937K

-126M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+33.48% upside

Dividends

By Acuity

Next Earnings

7 Aug 2026

Market Stats

By TradingEconomics

Market Cap

1.1B

4.1B

Previous open

24.86

Previous close

25.99

News Sentiment

By Acuity

40%

60%

90 / 342 Healthcare

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Jun 2026, 23:36 UTC

News
Social Media

MercadoLibre Inc. shares declined in after-market trading following news of a securities fraud investigation related to loan term disclosures, raising investor concerns.

30 Jun 2026, 23:36 UTC

News
Correlated Moves
Macro News
ETF Constituents

Vanguard Information Technology ETF's performance has been roughly flat during after-market hours, following a positive environment for technology stocks and the Nasdaq's rebound.

30 Jun 2026, 23:26 UTC

News
Correlated Moves

iShares iBoxx $ Investment Grade Corporate Bond ETF trades lower in after-market hours, amid a broader decline in U.S. equity indices and technology stocks.

30 Jun 2026, 23:21 UTC

News
Social Media

Micron Technology shares rose after hours, buoyed by a $250 million investment and significant revenue growth linked to AI chipmakers.

30 Jun 2026, 23:11 UTC

News

Comcast Corp shares rose in after-market trading, continuing an upward trend. The company's market cap now exceeds that of American Tower, ranking 135th in the S&P 500.

30 Jun 2026, 23:06 UTC

News
Correlated Moves

The US 10Y Treasury Bond Index is near unchanged in after-market hours, following a slight increase earlier in the day. The iShares 7-10 Year Treasury Bond ETF mirrors this stability.

30 Jun 2026, 23:06 UTC

Social Media
News

Microsoft shares rise in after-market hours, driven by strength in the Systems Software sub-sector and a new partnership with Chevron for a natural gas facility.

30 Jun 2026, 23:02 UTC

Social Media
News

Tesla Inc. shares are lower in after-market hours following Michael Burry's short position disclosure and a fatal incident involving one of its vehicles.

30 Jun 2026, 23:02 UTC

News

The iShares 20+ Year Treasury Bond ETF is lower in after-market trading, reflecting broader declines in U.S. indices and mixed market conditions.

30 Jun 2026, 23:02 UTC

News
ETF Constituents

Vanguard Growth ETF declines in after-market trading, driven by losses in top holdings NVIDIA, Tesla, and Meta, despite slight gains in the Nasdaq 100 Index.

30 Jun 2026, 23:01 UTC

News

Fox Corp has secured a $1 billion loan to fund its Roku acquisition. Shares are higher in after-market hours, aided by a strong Broadcasting sector.

30 Jun 2026, 22:51 UTC

News

Vanguard Total Bond Market ETF is lower in after-market hours, reflecting broader market pullbacks amid geopolitical tensions and fluctuating oil prices.

30 Jun 2026, 20:08 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline. Sharplink's acquisition of 10,000 ETH at $1,611 has not prevented the drop.

30 Jun 2026, 20:07 UTC

News

Vertex Pharmaceuticals is trading lower amid broader market pressures despite promising first-quarter results. Earlier in the session, shares briefly reached a high before declining.

30 Jun 2026, 20:07 UTC

Social Media
News

Intel Corp shares are advancing, driven by bullish semiconductor activity and increased buying interest. The stock reached a post-alert high of $131.14.

30 Jun 2026, 20:07 UTC

News
Correlated Moves
Social Media

NVIDIA shares rose following SemiAnalysis's bullish projection for data center revenue, expected to exceed consensus by 20% in fiscal 2027's second half.

30 Jun 2026, 20:07 UTC

News
Correlated Moves

Ethereum is trading lower, influenced by Bitcoin's decline and broader market pressures. Earlier, it dipped to a session low of $1,611.

30 Jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Apple Inc. shares are higher after the Supreme Court agreed to hear its appeal in the Epic Games antitrust case, potentially benefiting App Store fees.

30 Jun 2026, 20:03 UTC

News
Correlated Moves
Social Media

Analyst raises AMD price target to $615, citing strong AI demand. Shares are trading higher since Monday, reflecting positive market sentiment.

30 Jun 2026, 20:03 UTC

Social Media
Correlated Moves
ETF Constituents
News

Invesco QQQ Trust Series I advances today, driven by positive technology sector sentiment and strong performance from major contributors like AMD and Apple.

30 Jun 2026, 20:03 UTC

News
ETF Constituents

Health Care Select Sector SPDR Fund declines as health care underperforms, with Eli Lilly and Stryker contributing to the negative performance during Tuesday's session.

30 Jun 2026, 20:03 UTC

Correlated Moves
News
ETF Constituents

Germany's retail sales rose 1.1% in May, exceeding expectations. The iShares MSCI Germany ETF is gaining, supported by strong performances from key holdings.

30 Jun 2026, 20:02 UTC

Correlated Moves
Social Media
News

Applied Materials shares are higher today following price target increases, including Susquehanna's raise to $900 from $575, reflecting strong analyst sentiment.

30 Jun 2026, 20:01 UTC

News

Expedia Group Inc shares are lower today amid a decline in the Hotels, Resorts & Cruise Lines sector. Wells Fargo cut its price target to $303.

30 Jun 2026, 20:01 UTC

News

ASML Holding NV shares are higher amid positive sentiment and Bernstein's price target increase, supported by $518 billion in semiconductor infrastructure investments.

30 Jun 2026, 20:01 UTC

News
Correlated Moves

Intuitive Surgical shares are lower, reaching a four-week low amid declines in the Health Care Equipment sub-sector and volatility in the market.

30 Jun 2026, 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

30 Jun 2026, 19:56 UTC

News

Henry Schein announced a partnership with GoTu Technology to enhance dental workforce support, though shares are lower during Tuesday's session.

30 Jun 2026, 19:56 UTC

News
Correlated Moves

Concerns over currency volatility arise as the yen weakens against the dollar. EUR/HKD remains roughly flat since Monday's close amid broader market dynamics.

30 Jun 2026, 19:52 UTC

News

Costco Wholesale shares are lower, reaching a four-week low of $938.50, amid declines in the Consumer Staples Merchandise Retail sub-sector.

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

33.48% upside

12 Months Forecast

Average 34.33 USD  33.48%

High 42 USD

Low 23 USD

Based on 12 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Sentiment

By Acuity

90 / 342 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat